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Background: Familial hypercholesterolemia (FH) is a common inherited disorder leading to premature atherosclerosis. Current guidelines 
recommend initiating statin therapy in children with FH. Previous studies evaluated rosuvastatin in children aged ≥10 years (yrs), but its use in 
younger children has not yet been established. The purpose of this study was to assess the efficacy and tolerability of rosuvastatin in children with FH 
aged 6-17 yrs. Trial registration number: NCT01078675.
methods: This 2-year open-label, dose response titration study included male and female patients with FH, and fasting LDL-cholesterol (LDL-C) 
>190 mg/dL or >158 mg/dL plus other cardiovascular risk factors. Patients aged 6-9 yrs were statin naïve. All patients received rosuvastatin 5 
mg once daily, with up-titration to 10 mg (aged 6-9 yrs) or 20 mg (aged 10-17 yrs) based on LDL-C achieved. The primary efficacy variable was 
percentage change in LDL-C at 3, 12 and 24 months. Safety assessments included growth, sexual maturation and adverse events (AEs).
Results: 198 patients (6-9 yrs, n=64; 10 -13 yrs, n=72; and 14-17 yrs, n=62) were enrolled and received rosuvastatin. In the intent to treat 
population at 24 months, LDL-C was reduced by 43%, 45% and 35% in patients aged 6-9 yrs, 10-13 yrs and 14-17 yrs, respectively (p<0.001 for 
all three age groups vs baseline), and 48% of patients on 5 mg, 46% on 10 mg and 32% on 20 mg were at LDL-C goal <110 mg/dL. Arthralgia was 
reported in 3%, 10% and 5%, and myalgia in 0%, 7% and 10% of patients aged 6-9 yrs, 10-13 yrs and 14-17 yrs, respectively. The majority of AEs 
were mild. Nine (5%) patients had serious AEs, considered unrelated to treatment by the investigators. There were no clinically important changes 
in laboratory values, including hepatic biochemistry. One patient had creatinine increase from baseline ≥50% during treatment. This patient had a 
normal eGFR. There were no signs of impact of rosuvastatin treatment on height, weight, or sexual maturation.
conclusion: In FH patients aged 6-17 years, rosuvastatin 5-20 mg significantly reduced LDL-C compared with baseline over 2 years. The treatment 
was generally well tolerated with growth and sexual maturation remaining within normal ranges. 
